Common properties for propargylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: implications for the life prolonging effect of (–)deprenyl
(–)Deprenyl has been reported to prolong the life span of different animal species. Further, the drug effectively increases antioxidant enzyme activities such as superoxide dismutase (SOD) and catalase (CAT) in brain dopaminergic regions. We have found that the effect of the drug on antioxidant enzyme activities is highly dose dependent, increasing with an increasing dose, however, a higher dose becomes less effective and an excessive dose becomes adversely effective. Most importantly, an optimal dose for the effect varies widely depending on animal species, strain, sex, age and duration of the treatment, which may at least partly explain discrepancies reported among different studies in the past. From the parallelism of the dose-effect relationship of the drug between life span extension and increasing endogenous antioxidant enzyme activity, we have suggested that the above two effects of (–)deprenyl may be causally related. This review summarizes our past series of studies and also reports our very recent observation that other propargylamines such as rasagiline and (R)-N-(2-heptyl)-N-methylpropagylamine (R-2HMP) also share the property of enhancing antioxidant enzyme activities. Further, our most recent study has found that these propargylamines increase antioxidant enzyme activities not only in brain dopaminergic regions but in extra-brain dopaminergic tissues such as the heart and kidneys. These observations are discussed in relation to the life prolonging effect of (–)deprenyl reported in the past.
KeywordsOptimal Dose Antioxidant Enzyme Activity Dopaminergic System Neurobiol Aging Life Span Extension
Unable to display preview. Download preview PDF.
- Archer JR, Harrison DE (1996) L-deprenyl treatment in aged mice slightly increases life spans, and greatly reduces fecundity by aged males. J Gerontol 31A: B448-B453Google Scholar
- Bickford PC, Adams CE, Boyson SJ, Curella P, Gerhardt GA, Heron C, Ivy GO, Lin AMLY, Murphy MP, Poth K, Wallace DR, Young DA, Zahniser NR, Rose GM (1997) Long-term treatment of male F344 rats with deprenyl: Assessment of effects on longevity, behavior, and brain function. Neurobiol Aging 18: 309-318PubMedCrossRefGoogle Scholar
- Burek JD (1978) Pathology of aging rodents. CRC Press, West Palm BeachGoogle Scholar
- Carrillo MC, Kanai S, Kitani K, Ivy GO (2000a) A high dose of long term treatment with deprenyl loses its effect on antioxidant enzyme activities as well as on survivals of Fischer-344 rats. Life Sci (in press)Google Scholar
- Finberg JPM, Takashima T, Johnston JM, Commissiong JW (1998) Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuro Rep 9: 703-707Google Scholar
- Freisleben HJ, Neeb A, Lehr F, Ackermann H (1997) Influence of Selegiline and lipoic acid in the life expectancy of immunosuppressed mice. Arzneim-Forsch 47: 776-780Google Scholar
- Fujita S, Kitagawa H, Chiba M, Suzuki T, Ohta M, Kitani K (1985) Age and sex associated differences in the relative abundance of multiple species of cytochrome P-450 in rat liver microsomes – a separation by HPLC of hepatic microsomal cytochrome P-450 species. Biochem Pharmacol 34: 1861-1864PubMedCrossRefGoogle Scholar
- Gallagher IM, Clow A, Jenner P, Glover V (1999) Effect of long-term administration of pergolide and (-)deprenyl on age related decline in hole board activity and antioxidant enzymes in rats. Biogenic Amines 15: 379-393Google Scholar
- Ingram DK, Wiener HL, Chachich ME, Long JM, Hengemihle J, Gupta M (1993) Chronic treatment of aged mice with L-deprenyl produces marked MAO-B inhibition but no beneficial effects on survival, motor performance, or nigral lipofuscin accumulation. Neurobiol Aging 14: 431-440PubMedCrossRefGoogle Scholar
- Kitani K (1988) Drugs and the ageing liver. Life Chem Rep 6: 143-230Google Scholar
- Piantanelli L, Zaia A, Rossolini G, Vitiechi C, Testa R, Basso A, Antognini A (1994) Influence of L-deprenyl treatment on mouse survival kinetics. In: Zs-Nagy I, Harman D, Kitani K (eds) Pharmacology of aging processes. Method of assessment and potential interventions. Ann N Y Acad Sci 717: 72-78Google Scholar
- Ruehl WW, Bice D, Muggenburg B, Bruyette DD, Stevens DR (1994) L-Deprenyl and canine longevity: Evidence for an immune mechanism, and implications for human aging. 2nd Conference on Anti-Aging Medicine, Las Vegas, Abstract 25-26Google Scholar